FREE U.S. Shipping on $75+ Orders

Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/ myalgic encephalomyelitis (cfs/me)

1 Star2 Stars3 Stars4 Stars5 Stars (8 votes, average: 4.25 out of 5)
Loading...

By W. M. Mitchell

Abstract

Chronic fatigue syndrome/ Myalgic encephalomyelitis (CFS/ME) is a poorly understood seriously debilitating disorder in which disabling fatigue is an universal symptom in combination with a variety of variable symptoms. The only drug in advanced clinical development is rintatolimod, a mismatched double stranded polymer of RNA (dsRNA).

Rintatolimod is a restricted Toll-Like Receptor 3 (TLR3) agonist lacking activation of other primary cellular inducers of innate immunity (e.g.- cytosolic helicases). Rintatolimod also activates interferon induced proteins that require dsRNA for activity (e.g.- 2′-5′ adenylate synthetase, protein kinase R).

Rintatolimod has achieved statistically significant improvements in primary endpoints in Phase II and Phase III double-blind, randomized, placebo-controlled clinical trials with a generally well tolerated safety profile and supported by open-label trials in the United States and Europe. The chemistry, mechanism of action, clinical trial data, and current regulatory status of rintatolimod for CFS/ME including current evidence for etiology of the syndrome are reviewed.

Source: Mitchell WM. Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/ myalgic encephalomyelitis (cfs/me). Expert Rev Clin Pharmacol. 2016 Apr 5. [Epub ahead of print]

ProHealth CBD Store

 

Are you vitamin d deficient?

1 Star2 Stars3 Stars4 Stars5 Stars (8 votes, average: 4.25 out of 5)
Loading...



3 thoughts on “Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/ myalgic encephalomyelitis (cfs/me)”

  1. BarbRishaw says:

    I appreciate that this article is an abstract and therefore gives us an overview of the actual report. But in this case the result is an article that reveals little new in terms of usable information. I would have liked to have seen some specific numbers quoted on the “statistically significant improvements” of study subjects. As a (albeit mild) sufferer of me/cfs it’s those details that are of importance to me.

  2. ericaverrillo says:

    Here is a longer article that gives a lot more detail, as well as easy-to-read charts. https://www.sciforschenonline.org/journals/drug/JDRD-1-103.php

  3. zuheb.sm says:

    Has this drug passed trials and approval process in any country around the world? Is this commercially available via prescriptions anywhere?

Leave a Reply